Development and Validation of a Model to Determine Risk of Progression of Barrett's Esophagus to Neoplasia

Sravanthi Parasa, Sreekar Vennalaganti, Srinivas Gaddam, Prashanth Vennalaganti, Patrick Young, Neil Gupta, Prashanthi Thota, Brooks Cash, Sharad Mathur, Richard Sampliner, Fouad Moawad, David Lieberman, Ajay Bansal, Kevin F. Kennedy, John Vargo, Gary Falk, Manon Spaander, Marco Bruno, Prateek Sharma

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background & Aims: A system is needed to determine the risk of patients with Barrett's esophagus for progression to high-grade dysplasia (HGD) and esophageal adenocarcinoma (EAC). We developed and validated a model to determine of progression to HGD or EAC in patients with BE, based on demographic data and endoscopic and histologic findings at the time of index endoscopy. Methods: We performed a longitudinal study of patients with BE at 5 centers in United States and 1 center in Netherlands enrolled in the Barrett's Esophagus Study database from 1985 through 2014. Patients were excluded from the analysis if they had less than 1 year of follow-up, were diagnosed with HGD or EAC within the past year, were missing baseline histologic data, or had no intestinal metaplasia. Seventy percent of the patients were used to derive the model and 30% were used for the validation study. The primary outcome was development of HGD or EAC during the follow-up period (median, 5.9 years). Survival analysis was performed using the Kaplan-Meier method. We assigned a specific number of points to each BE risk factor, and point totals (scores) were used to create categories of low, intermediate, and high risk. We used Cox regression to compute hazard ratios and 95% confidence intervals to determine associations between risk of progression and scores. Results: Of 4584 patients in the database, 2697 were included in our analysis (84.1% men; 87.6% Caucasian; mean age, 55.4 ± 20.1 years; mean body mass index, 27.9 ± 5.5 kg/m2; mean length of BE, 3.7 ± 3.2 cm). During the follow-up period, 154 patients (5.7%) developed HGD or EAC, with an annual rate of progression of 0.95%. Male sex, smoking, length of BE, and baseline-confirmed low-grade dysplasia were significantly associated with progression. Scores assigned identified patients with BE that progressed to HGD or EAC with a c-statistic of 0.76 (95% confidence interval, 0.72–0.80; P <.001). The calibration slope was 0.9966 (P =.99), determined from the validation cohort. Conclusions: We developed a scoring system (Progression in Barrett's Esophagus score) based on male sex, smoking, length of BE, and baseline low-grade dysplasia that identified patients with BE at low, intermediate, and high risk for HGD or EAC. This scoring system might be used in management of patients.

Original languageEnglish (US)
Pages (from-to)1282-1289.e2
JournalGastroenterology
Volume154
Issue number5
DOIs
StatePublished - Apr 1 2018

Fingerprint

Barrett Esophagus
Adenocarcinoma
Neoplasms
Smoking
Databases
Confidence Intervals
Validation Studies
Metaplasia
Survival Analysis
Netherlands
Calibration
Endoscopy
Longitudinal Studies
Body Mass Index
Demography

Keywords

  • Esophageal Cancer
  • Multi-Center Trial
  • PIB
  • Progression in Barrett's Esophagus score

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Parasa, S., Vennalaganti, S., Gaddam, S., Vennalaganti, P., Young, P., Gupta, N., ... Sharma, P. (2018). Development and Validation of a Model to Determine Risk of Progression of Barrett's Esophagus to Neoplasia. Gastroenterology, 154(5), 1282-1289.e2. https://doi.org/10.1053/j.gastro.2017.12.009

Development and Validation of a Model to Determine Risk of Progression of Barrett's Esophagus to Neoplasia. / Parasa, Sravanthi; Vennalaganti, Sreekar; Gaddam, Srinivas; Vennalaganti, Prashanth; Young, Patrick; Gupta, Neil; Thota, Prashanthi; Cash, Brooks; Mathur, Sharad; Sampliner, Richard; Moawad, Fouad; Lieberman, David; Bansal, Ajay; Kennedy, Kevin F.; Vargo, John; Falk, Gary; Spaander, Manon; Bruno, Marco; Sharma, Prateek.

In: Gastroenterology, Vol. 154, No. 5, 01.04.2018, p. 1282-1289.e2.

Research output: Contribution to journalArticle

Parasa, S, Vennalaganti, S, Gaddam, S, Vennalaganti, P, Young, P, Gupta, N, Thota, P, Cash, B, Mathur, S, Sampliner, R, Moawad, F, Lieberman, D, Bansal, A, Kennedy, KF, Vargo, J, Falk, G, Spaander, M, Bruno, M & Sharma, P 2018, 'Development and Validation of a Model to Determine Risk of Progression of Barrett's Esophagus to Neoplasia', Gastroenterology, vol. 154, no. 5, pp. 1282-1289.e2. https://doi.org/10.1053/j.gastro.2017.12.009
Parasa S, Vennalaganti S, Gaddam S, Vennalaganti P, Young P, Gupta N et al. Development and Validation of a Model to Determine Risk of Progression of Barrett's Esophagus to Neoplasia. Gastroenterology. 2018 Apr 1;154(5):1282-1289.e2. https://doi.org/10.1053/j.gastro.2017.12.009
Parasa, Sravanthi ; Vennalaganti, Sreekar ; Gaddam, Srinivas ; Vennalaganti, Prashanth ; Young, Patrick ; Gupta, Neil ; Thota, Prashanthi ; Cash, Brooks ; Mathur, Sharad ; Sampliner, Richard ; Moawad, Fouad ; Lieberman, David ; Bansal, Ajay ; Kennedy, Kevin F. ; Vargo, John ; Falk, Gary ; Spaander, Manon ; Bruno, Marco ; Sharma, Prateek. / Development and Validation of a Model to Determine Risk of Progression of Barrett's Esophagus to Neoplasia. In: Gastroenterology. 2018 ; Vol. 154, No. 5. pp. 1282-1289.e2.
@article{fd277e2ca5c644cc87466755c6f1baf3,
title = "Development and Validation of a Model to Determine Risk of Progression of Barrett's Esophagus to Neoplasia",
abstract = "Background & Aims: A system is needed to determine the risk of patients with Barrett's esophagus for progression to high-grade dysplasia (HGD) and esophageal adenocarcinoma (EAC). We developed and validated a model to determine of progression to HGD or EAC in patients with BE, based on demographic data and endoscopic and histologic findings at the time of index endoscopy. Methods: We performed a longitudinal study of patients with BE at 5 centers in United States and 1 center in Netherlands enrolled in the Barrett's Esophagus Study database from 1985 through 2014. Patients were excluded from the analysis if they had less than 1 year of follow-up, were diagnosed with HGD or EAC within the past year, were missing baseline histologic data, or had no intestinal metaplasia. Seventy percent of the patients were used to derive the model and 30{\%} were used for the validation study. The primary outcome was development of HGD or EAC during the follow-up period (median, 5.9 years). Survival analysis was performed using the Kaplan-Meier method. We assigned a specific number of points to each BE risk factor, and point totals (scores) were used to create categories of low, intermediate, and high risk. We used Cox regression to compute hazard ratios and 95{\%} confidence intervals to determine associations between risk of progression and scores. Results: Of 4584 patients in the database, 2697 were included in our analysis (84.1{\%} men; 87.6{\%} Caucasian; mean age, 55.4 ± 20.1 years; mean body mass index, 27.9 ± 5.5 kg/m2; mean length of BE, 3.7 ± 3.2 cm). During the follow-up period, 154 patients (5.7{\%}) developed HGD or EAC, with an annual rate of progression of 0.95{\%}. Male sex, smoking, length of BE, and baseline-confirmed low-grade dysplasia were significantly associated with progression. Scores assigned identified patients with BE that progressed to HGD or EAC with a c-statistic of 0.76 (95{\%} confidence interval, 0.72–0.80; P <.001). The calibration slope was 0.9966 (P =.99), determined from the validation cohort. Conclusions: We developed a scoring system (Progression in Barrett's Esophagus score) based on male sex, smoking, length of BE, and baseline low-grade dysplasia that identified patients with BE at low, intermediate, and high risk for HGD or EAC. This scoring system might be used in management of patients.",
keywords = "Esophageal Cancer, Multi-Center Trial, PIB, Progression in Barrett's Esophagus score",
author = "Sravanthi Parasa and Sreekar Vennalaganti and Srinivas Gaddam and Prashanth Vennalaganti and Patrick Young and Neil Gupta and Prashanthi Thota and Brooks Cash and Sharad Mathur and Richard Sampliner and Fouad Moawad and David Lieberman and Ajay Bansal and Kennedy, {Kevin F.} and John Vargo and Gary Falk and Manon Spaander and Marco Bruno and Prateek Sharma",
year = "2018",
month = "4",
day = "1",
doi = "10.1053/j.gastro.2017.12.009",
language = "English (US)",
volume = "154",
pages = "1282--1289.e2",
journal = "Gastroenterology",
issn = "0016-5085",
publisher = "W.B. Saunders Ltd",
number = "5",

}

TY - JOUR

T1 - Development and Validation of a Model to Determine Risk of Progression of Barrett's Esophagus to Neoplasia

AU - Parasa, Sravanthi

AU - Vennalaganti, Sreekar

AU - Gaddam, Srinivas

AU - Vennalaganti, Prashanth

AU - Young, Patrick

AU - Gupta, Neil

AU - Thota, Prashanthi

AU - Cash, Brooks

AU - Mathur, Sharad

AU - Sampliner, Richard

AU - Moawad, Fouad

AU - Lieberman, David

AU - Bansal, Ajay

AU - Kennedy, Kevin F.

AU - Vargo, John

AU - Falk, Gary

AU - Spaander, Manon

AU - Bruno, Marco

AU - Sharma, Prateek

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Background & Aims: A system is needed to determine the risk of patients with Barrett's esophagus for progression to high-grade dysplasia (HGD) and esophageal adenocarcinoma (EAC). We developed and validated a model to determine of progression to HGD or EAC in patients with BE, based on demographic data and endoscopic and histologic findings at the time of index endoscopy. Methods: We performed a longitudinal study of patients with BE at 5 centers in United States and 1 center in Netherlands enrolled in the Barrett's Esophagus Study database from 1985 through 2014. Patients were excluded from the analysis if they had less than 1 year of follow-up, were diagnosed with HGD or EAC within the past year, were missing baseline histologic data, or had no intestinal metaplasia. Seventy percent of the patients were used to derive the model and 30% were used for the validation study. The primary outcome was development of HGD or EAC during the follow-up period (median, 5.9 years). Survival analysis was performed using the Kaplan-Meier method. We assigned a specific number of points to each BE risk factor, and point totals (scores) were used to create categories of low, intermediate, and high risk. We used Cox regression to compute hazard ratios and 95% confidence intervals to determine associations between risk of progression and scores. Results: Of 4584 patients in the database, 2697 were included in our analysis (84.1% men; 87.6% Caucasian; mean age, 55.4 ± 20.1 years; mean body mass index, 27.9 ± 5.5 kg/m2; mean length of BE, 3.7 ± 3.2 cm). During the follow-up period, 154 patients (5.7%) developed HGD or EAC, with an annual rate of progression of 0.95%. Male sex, smoking, length of BE, and baseline-confirmed low-grade dysplasia were significantly associated with progression. Scores assigned identified patients with BE that progressed to HGD or EAC with a c-statistic of 0.76 (95% confidence interval, 0.72–0.80; P <.001). The calibration slope was 0.9966 (P =.99), determined from the validation cohort. Conclusions: We developed a scoring system (Progression in Barrett's Esophagus score) based on male sex, smoking, length of BE, and baseline low-grade dysplasia that identified patients with BE at low, intermediate, and high risk for HGD or EAC. This scoring system might be used in management of patients.

AB - Background & Aims: A system is needed to determine the risk of patients with Barrett's esophagus for progression to high-grade dysplasia (HGD) and esophageal adenocarcinoma (EAC). We developed and validated a model to determine of progression to HGD or EAC in patients with BE, based on demographic data and endoscopic and histologic findings at the time of index endoscopy. Methods: We performed a longitudinal study of patients with BE at 5 centers in United States and 1 center in Netherlands enrolled in the Barrett's Esophagus Study database from 1985 through 2014. Patients were excluded from the analysis if they had less than 1 year of follow-up, were diagnosed with HGD or EAC within the past year, were missing baseline histologic data, or had no intestinal metaplasia. Seventy percent of the patients were used to derive the model and 30% were used for the validation study. The primary outcome was development of HGD or EAC during the follow-up period (median, 5.9 years). Survival analysis was performed using the Kaplan-Meier method. We assigned a specific number of points to each BE risk factor, and point totals (scores) were used to create categories of low, intermediate, and high risk. We used Cox regression to compute hazard ratios and 95% confidence intervals to determine associations between risk of progression and scores. Results: Of 4584 patients in the database, 2697 were included in our analysis (84.1% men; 87.6% Caucasian; mean age, 55.4 ± 20.1 years; mean body mass index, 27.9 ± 5.5 kg/m2; mean length of BE, 3.7 ± 3.2 cm). During the follow-up period, 154 patients (5.7%) developed HGD or EAC, with an annual rate of progression of 0.95%. Male sex, smoking, length of BE, and baseline-confirmed low-grade dysplasia were significantly associated with progression. Scores assigned identified patients with BE that progressed to HGD or EAC with a c-statistic of 0.76 (95% confidence interval, 0.72–0.80; P <.001). The calibration slope was 0.9966 (P =.99), determined from the validation cohort. Conclusions: We developed a scoring system (Progression in Barrett's Esophagus score) based on male sex, smoking, length of BE, and baseline low-grade dysplasia that identified patients with BE at low, intermediate, and high risk for HGD or EAC. This scoring system might be used in management of patients.

KW - Esophageal Cancer

KW - Multi-Center Trial

KW - PIB

KW - Progression in Barrett's Esophagus score

UR - http://www.scopus.com/inward/record.url?scp=85044590260&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044590260&partnerID=8YFLogxK

U2 - 10.1053/j.gastro.2017.12.009

DO - 10.1053/j.gastro.2017.12.009

M3 - Article

C2 - 29273452

AN - SCOPUS:85044590260

VL - 154

SP - 1282-1289.e2

JO - Gastroenterology

JF - Gastroenterology

SN - 0016-5085

IS - 5

ER -